Calypte und die Zeit nach AIDS2004 in Bangkok

 

Hey Joelu,

letztes Jahr hast du auch die ganze Zeit negative Beiträge geschrieben !!!!!!

Ich ging im Dezember mit 1400%(calypte) in Urlaub und habe immer noch nicht mal 50% der Gewinne ausgeben können, ich würde lieber mal bisschen Traden anstatt die Leute hier zu Unterhalten.


Nur mal so ein Tip !!!!

Der nächste Zock kommt bald ......... Geduld macht Reich  

While many countries have their own regulatory approval processes,  others
     look to the results of WHO  evaluations  for  guidance.  The World  Health
     Organization  ("WHO")  serves  as  both  a  quasi-regulatory  body  and  a
     potential  funding  source for many  developing  countries  that might not
     otherwise possess the regulatory  infrastructure or financial resources to
     avail  themselves  of products for the  diagnosis and treatment of HIV and
     AIDS.  Calypte believes that a strong performance of the rapid urine tests
     in  a  WHO  evaluation  would  be  an  equally,  if  not  more,  effective
     demonstration  of the viability of urine testing for HIV antibodies as the
     evaluation we earlier contemplated for the EIA and Western Blot algorithm.
     We have been  advised  by WHO that its bulk  procurement  program  for HIV
     tests focuses on diagnostic and blood donation  screening tests capable of
     detecting  the presence of both HIV-1 and HIV-2  antibodies.  Although WHO
     has  previously  reported  the results of its Phase 1 trials of  Calypte's
     current  HIV-1 EIA and Western Blot tests on its website,  WHO has advised
     us  that,  in  principle,  it  views  those  tests  as  suitable  only for
     surveillance   purposes  and   therefore   not  eligible  for  WHO's  bulk
     procurement program. We anticipate,  however,  that certain countries will
     look to the results of WHO  evaluations for guidance on the potential uses
     of urine tests and for this  reason the Company  wants to continue to work
     with WHO. In our view, the attributes of Calypte's  planned  HIV-1/2 rapid
     tests as discussed above for use with urine,  blood and oral fluid samples
     will more  closely  match  the needs of the  developing  world  and,  once
     evaluated by WHO, are more likely to meet its bulk procurement eligibility
     criteria.  For  these  reasons,  we  plan,  as a part  of our  rapid  test
     commercialization  process,  to request  that WHO focus its  resources  on
     evaluation of the technology employed by the rapid tests.

Serum  Western  Blot Sales Sales of our Serum  Western  Blot  supplemental  test
accounted for 36% and 32% of our revenues for the six months ended June 30, 2004
and the year ended  December 31, 2003,  respectively.  In  mid-April  2004,  our
primary domestic  distributor for our serum Western Blot was acquired by another
entity and  informed us that it would no longer serve as a U.S.  distributor  of
our product.  We did not appoint a successor  distributor  and, while several of
the former  distributor's  customers are now  purchasing  the serum Western Blot
directly from us, we do not know how many of these customers will continue using
our test.  Furthermore,  while the Western Blot  supplemental test is key in the
FDA-regulated  testing algorithm today, it is unclear if, or when, rapid testing
or other testing formats may substantially  replace ELISA-based testing. If that
trend  occurs,  the  need  for  Western  Blot  supplemental  tests  may  also be
significantly reduced or eliminated.

Viral  Lysate  Sales In 2002,  we sold  approximately  $0.2 million of HIV viral
lysate, a component used in manufacturing our Western Blot products and which we
have sold  sporadically  to another  manufacturer  of serum-based HIV diagnostic
tests and other parties.  Such sales  represented  approximately 6% of our total
revenues in 2002 and were  negligible  in 2003 and in the first half of 2004. We
do not consider such sales to be a core component of our on-going business.

RESULTS OF OPERATIONS

Years Ended December 31, 2003 and 2002

Calypte's  2003  revenues  totaled $3.5 million  compared  with $3.7 million for
2002, a decrease of $0.2 million or 6%.  Screening  test  revenues  increased by
$508,000 or 30%.  Sales of the screening  tests to insurance  company  reference
labs  increased  by  $528,000  or 37%.  During the fourth  quarter of 2003,  our
largest customer purchased remaining  consignment inventory on hand and switched
to a standard contractual  relationship.  This increased our fourth quarter 2003
revenue by approximately $167,000.  Additionally,  screening tests revenues were
lower than  historical  levels in 2002 due  primarily  to a reduction in product
availability as a result of our wind-down and restart.

International sales of our screening tests accounted for approximately  $173,000
and $143,000 in 2003 and 2002,  respectively.  International  sales  amounted to
approximately  5% of  total  revenue  in  2003  and  4%  in  2002.  Our  primary
international  sales  in both  2003 and 2002  were to our  Chinese  distributor.
Domestic  diagnostic and direct screening test sales were  insignificant in both
2003 and 2002.

Revenue from the sale of our supplemental  tests and viral lysate decreased $0.7
million or 35% in 2003  compared with 2002.  Urine Western Blot sales  decreased
$7,000 or 5%, from  $162,000 in 2002 to $154,000  in 2003.  Serum  Western  Blot
sales decreased by 30% or approximately  $0.5 million compared with 2002 levels.
The decrease is due to product  availability issues related to the wind-down and
restart,  as well as to the  loss  of  bioMerieux  as a  distributor  after  our
restart.  We engaged  Adaltis Inc. as our new  distributor in the second half of
2002, but have yet to regain our  pre-wind-down  market share, as there have not
been significant sales by Adaltis.

Sales of HIV viral lysate,  a component we use in the  production of our Western
Blot products and which we previously  sporadically sold to another manufacturer
of serum-based HIV diagnostic tests and other parties, decreased by $0.2 million
or nearly 100% compared to 2002 levels.  The sale of viral lysate  accounted for
approximately  6% of 2002  revenues.  We have not  sold  viral  lysate  since we
restarted  our  operations  in mid-2002  and we do not consider its sale to be a
core component of our on-going business.







Allowance  for  Doubtful  Accounts  We  maintain  an  allowance  for
           doubtful  accounts on a specific  account  identification  basis for
           estimated  losses  resulting  from the inability of our customers to
           make required payments.  If the financial condition of our customers
           were to deteriorate,  resulting in an impairment of their ability to
           make payments,  or regulatory  issues with our products were raised,
           additional allowances may be required.

     o     Inventory  Valuation  We  adjust  the  value  of our  inventory  for
           estimated  obsolescence  or  unmarketable  inventory  equal  to  the
           difference  between the cost of inventory and the  estimated  market
           value  based  upon  assumptions   about  future  demand  and  market
           conditions  and  development  of new  products  by our  competitors.
           Further,  since we have  continued to incur negative gross profit on
           an annual basis,  and have high fixed  manufacturing  costs, we also
           review our  inventories  for lower of cost or market  valuation.  If
           actual market  conditions are less favorable than those projected by
           management,  additional  inventory  write-downs may be required.  We
           increased  the  inventory  of our  urine  screening  test  prior  to
           transferring its manufacturing to our Rockville, MD facility; demand
           for this  product  could  fall  significantly  below the  historical
           levels on which the production was based,  in which case we may have
           built excess  inventory that we may have to dispose of at additional
           cost, or at a loss.

     o     Deferred Tax Asset Realization We record a full valuation  allowance
           to reduce our  deferred tax assets to the amount that is more likely
           than not to be realized.  While we have  considered  future  taxable
           income and ongoing  prudent and feasible tax planning  strategies in
           assessing the need for the valuation allowance, in the event we were
           to  determine  that we would be able to  realize  our  deferred  tax
           assets  in the  future  in excess  of its net  recorded  amount,  an
           adjustment  to the deferred tax asset would  increase  income in the
           period such determination was made.

WIND-DOWN AND RESTART

In mid-April 2002, as a result of insufficient  cash to continue our operations,
we announced  that we were winding down our  operations  and might have to cease
our operations entirely and file for bankruptcy.  We immediately  furloughed all
but a few  manufacturing  and  administrative  employees,  making no  separation
payments or payments of accrued  vacation to any  employees.  The  manufacturing
employees who were retained  completed certain lots of in-process  inventory and
readied them for sale and were then also  furloughed.  Immediately  prior to the
restart,  we had  terminated  all but 5  employees,  retaining  only the minimum
necessary to ensure  regulatory  compliance for our facilities should additional
financing  enabling a restart  become  available.  Upon  receipt of the  initial
financing  commitment that permitted the restart, we recalled key management and
manufacturing  employees  and began the  process of resuming  our  manufacturing
operations.  Other employees,  such as administrative and sales personnel,  were
recalled in stages as  required  and as funding  permitted.  We had 73 full- and
part-time  employees  prior to our  wind-down  and,  prior to the closure of our
Alameda,  California manufacturing facility in June 2004, we had returned to our
approximate  pre-wind-down  headcount  levels.  Not  all  of  the  pre-wind-down
employees  were  rehired,  and we believe our current  complement  is  generally
sufficient to meet our operational needs.

The costs of the wind-down and restart are difficult to quantify precisely. 2002
operations  reflect  both the  inherent  inefficiencies  in the  restart  of our
manufacturing  processes,  including  the excess  overhead  and  capacity  costs
incurred,  as well as the lower sales  demand  resulting  from  abnormally-large
purchases prior to the wind-down,  and the time required to rebuild demand among
customers  concerned  with  our  longer-term  stability.  Additionally,  we have
incurred  incremental  general and  administrative  costs,  as well as financial
costs in obtaining new capital  investments and financing in the Company,  (some
of them non-cash) attributable to consultants engaged in the restart process and
thereafter in investor relations initiatives within the financial community, and
in other areas of expertise.







RISK FACTORS

See Risk Factors beginning on page 5 of this Prospectus.

                     MANAGEMENT'S DISCUSSION AND ANALYSIS

The following  information  should be read in conjunction  with the consolidated
financial  statements  and  related  notes that are  provided  as a part of this
Prospectus.

Information we provide in this  Prospectus or statements  made by our directors,
officers or employees may  constitute  "forward-looking"  statements  and may be
subject  to  numerous  risks  and  uncertainties.  Any  statements  made in this
Prospectus,  including any statements incorporated herein by reference, that are
not statements of historical fact are forward-looking statements (including, but
not limited to,  statements  concerning  the  characteristics  and growth of our
market  and  customers,  our  objectives  and plans for  future  operations  and
products  and  our  liquidity  and  capital  resources).   Such  forward-looking
statements are based on current  expectations  and are subject to  uncertainties
and other  factors  which may involve  known and unknown  risks that could cause
actual  results of  operations  to differ  materially  from those  projected  or
implied. Further, certain forward-looking  statements are based upon assumptions
about future events which may not prove to be accurate.  Risks and uncertainties
inherent in forward looking statements include, but are not limited to:

     o     fluctuations in our operating results;

     o     announcements of technological  innovations or new products which we
           or our competitors make;

     o     FDA and international regulatory actions;

     o     developments with respect to patents or proprietary rights;

     o     changes in stock market analysts' recommendations regarding Calypte,
           other medical  products  companies or the medical  product  industry
           generally;

     o     changes in domestic or international  conditions  beyond our control
           that may disrupt our or our customers' or  distributors'  ability to
           meet contractual obligations;

     o     changes in health care policy in the United States or abroad;

     o     our ability to obtain additional financing as necessary to fund both
           our long- and short-term business plans;

     o     fluctuations in market demand for and supply of our products;

     o     public  concern  as to the  safety  of  products  that we or  others
           develop and public concern regarding HIV and AIDS;

     o     availability of  reimbursement  for use of our products from private
           health insurers,  governmental health administration authorities and
           other third-party payors; and

     o     price and volume  fluctuations in the stock market at large which do
           not relate to our operating performance.

The forward-looking information set forth in this Prospectus is as of October 6,
2004, and Calypte  undertakes no duty to update this information.  Should events
occur  subsequent  to  October  6,  2004 that make it  necessary  to update  the
forward-looking   information   contained  in  this   Prospectus,   the  updated
forward-looking  information will be filed with the SEC in a Quarterly Report on
Form 10-QSB,  as an earnings or other  release  included as an exhibit to a Form
8-K or as an amendment  to this  registration  statement,  each of which will be
available at the SEC's website at www.sec.gov or our website at www.calypte.com.
More information  about potential  factors that could affect Calypte's  business
and  financial  results is  included  in the  section  entitled  "Risk  Factors"
beginning on page 5 of this Prospectus.

OVERVIEW AND OUTLOOK

Since 1998,  following  FDA approval for both the current  ELISA  screening  and
supplemental tests,  Calypte has been marketing and selling in the United States
the only available FDA-approved urine-based HIV testing method. We have received
regulatory approval to sell our ELISA tests in China, Malaysia,  Indonesia,  and
in  parts  of  Africa.  Unfortunately,  these  laboratory-based  tests  have not
received  significant  acceptance in those  markets.  We believe that there is a
small established  market for our current ELISA tests in the United States and a
potential  market  in  certain  foreign   countries  with  established   medical
diagnostic and treatment  infrastructures,  as well. We believe,  however,  that
rapid tests are more  suitable  in many of the  countries  in which  HIV/AIDS is
epidemic,  and  particularly  so in  sub-Saharan  Africa  and  the  "next  wave"
countries of Russia, China, India and in northern Africa.  Consequently,  we are
now actively working to commercialize  our HIV rapid test products and to obtain
requisite  regulatory  approvals to introduce these products in these countries,
as well as in other  international  markets.  There can be no assurance  that we
will achieve or sustain significant revenues from sales of HIV diagnostic tests,
internationally  or  domestically,  or from other new products we may develop or
introduce.





o     The ability to obtain FDA or other regulatory approvals;

     o     The  ability  to  manufacture  products  that  meet  applicable  FDA
           requirements (i.e., good manufacturing practices);

     o     Access to adequate capital;

     o     The ability to attract and retain qualified personnel; and

     o     The availability of patent protection.

We expect competition to intensify as technological advances are made and become
more  widely  known,  and as new  products  reach the market.  Furthermore,  new
testing  methodologies could be developed in the future that render our products
impractical,  uneconomical  or  obsolete.  There  can be no  assurance  that our
competitors  will not  succeed  in  developing  or  marketing  technologies  and
products that are more  effective than those we develop or that would render our
technologies and products obsolete or otherwise  commercially  unattractive.  In
addition,  there can be no assurance  that our  competitors  will not succeed in
obtaining regulatory approval for these products,  or introduce or commercialize
them  before we can do so.  These  developments  could have a  material  adverse
effect on our business, financial condition and results of operations.

Significant  competitors  for our current and  developmental  stage HIV antibody
tests are Abbott  Laboratories,  bioMerieux,  the Ortho Diagnostics  division of
Johnson & Johnson and Bio-Rad  Laboratories,  which sell blood-based  HIV-1 EIAs
and Orasure Technologies,  Inc., which sells FDA-approved HIV tests including an
oral fluid-based  laboratory test, a blood-based  rapid HIV-1 and HIV-2 test and
an oral fluid-based rapid HIV-1 test.  MedMira and Trinity Biotech each recently
received FDA approval to sell rapid HIV-1 blood tests in the United  States.  We
believe other  companies may seek FDA approval to sell competing rapid HIV tests
in the future.

Several  companies market or have announced plans to market  blood-based or oral
fluid-based  HIV rapid  tests in the  United  States and  abroad.  We expect the
number of blood-based and oral  fluid-based HIV rapid tests to increase as these
tests become more widely accepted.  We are not aware of any companies  marketing
or planning to market  competing  urine-based HIV rapid tests,  although,  Murex
Corporation,  owned by  Abbott  Laboratories,  has  previously  announced  urine
capability for an HIV test.

Outside of the United States,  where  regulatory  requirements for HIV screening
tests are sometimes less  demanding,  a much wider range of  competitors  may be
found. Manufacturers from Japan, Canada, Europe, and Australia offer a number of
HIV screening  tests in those  markets  including  HIV-1 and HIV-2 tests,  rapid
tests and other  non-EIA  format  tests.  There  can be no  assurances  that our
products will compete  effectively against these products in foreign markets, or
that these competing products will not achieve FDA approval.

EMPLOYEES

As of September 24, 2004,  following  the  cessation of our Alameda,  California
manufacturing  operations,  we had an aggregate  of 51 full time,  part time and
temporary  employees,  11 of whom were  engaged  in or  directly  supported  our
research  and  development  activities,   31  of  whom  were  in  manufacturing,
manufacturing support and quality assurance,  one of whom was in marketing and 9
of whom were in administration.  Our employees are not represented by a union or
collective  bargaining  entity.  We believe our relations with our employees are
good.




WHO serves as both a  quasi-regulatory  body and a potential  funding source for
many  developing  countries  that might not  otherwise  possess  the  regulatory
infrastructure  or financial  resources to avail  themselves of products for the
diagnosis and treatment of HIV and AIDS. We believe that a strong performance of
our proposed rapid urine tests in a WHO evaluation  would be an equally,  if not
more,  effective  demonstration  of the  viability  of  urine  testing  for  HIV
antibodies than the evaluation we earlier  contemplated  for our ELISA tests. We
have been advised by WHO that its bulk procurement program for HIV tests focuses
on  diagnostic  and blood  donation  screening  tests  capable of detecting  the
presence  of both  HIV-1  and  HIV-2  antibodies.  Although  WHO has  previously
reported  the results of its Phase 1 trials of our current EIA and Western  Blot
tests on its  website,  WHO has advised us that,  in  principle,  it views those
tests as suitable only for surveillance  purposes and therefore not eligible for
WHO's bulk procurement  program.  We anticipate that certain countries will look
to the results of WHO  evaluations  for guidance on the potential  uses of urine
tests and for this  reason we intend to  continue  to work with WHO.  We believe
that the  attributes  of our rapid  tests for  HIV-1/2 in urine,  oral fluid and
whole blood  samples more closely match the needs of the  developing  world and,
once evaluated by WHO, are more likely to meet its bulk procurement  eligibility
criteria.   For  these   reasons,   we  plan,  as  a  part  of  our  rapid  test
commercialization process, to request that WHO focus its resources on evaluation
of the technology employed by the rapid tests.

We  have   obtained   regulatory   approval  for  our  ELISA  tests  in  certain
international  markets including  Malaysia,  China,  Indonesia,  the Republic of
South  Africa,  Kenya and  Uganda.  These  approvals  validate  the use of urine
testing in the  diagnosis of HIV. We believe that the two largest  international
markets  for our urine  ELISA  tests are (1) China,  where our ELISA  tests have
already been granted approval as a medical device and where we are attempting to
achieve  expanded  access to governmental  testing  applications by obtaining an
additional  Biologics Branch approval,  and (2) Russia, where we are considering
expansion.  Although  we have  obtained  approval  for our urine  ELISA tests in
certain African  countries and are engaged in the approval process in others, we
have  determined  that most  hospitals  and voluntary  testing  centers in these
countries,  due to their limited  infrastructure,  can best utilize our proposed
HIV urine rapid test. Even though many hospitals, clinics or testing centers may
recognize the advantages of and prefer urine  testing,  we believe that there is
negligible demand for our current urine ELISA tests as they would prefer to wait
for the  availability  of our  announced  rapid  test  products  than  implement
procedures applicable to the current lab-based urine testing alternative.

We have not begun the regulatory process for our dipstick-format  rapid tests in
any target market,  although we have begun  preparations  for clinical trials in
China.  We believe that the regulatory  processes in certain  foreign  countries
having a greater  prevalence  of HIV will be faster,  which  should  result in a
quicker  timeframe  for  approval  and right to bring our rapid tests to market.
Consequently,  we plan to focus our efforts on obtaining approvals for our rapid
tests in those  countries.  We  expect  that our  initial  focus  for  obtaining
approval of our rapid tests will be in Africa and the key "next wave"  countries
of China, Russia and, subsequently,  India. In China,  regulatory approval for a
product  is  granted  only for  products  manufactured  in China and only to the
Chinese manufacturer of such product. As a result, for us to maintain control of
our products in China,  we plan to  manufacture  our products in China through a
joint venture involving BTBP.

We  anticipate  that  there  will  be  distinct   approval   processes  for  the
professional market (hospitals,  clinics, testing centers and government testing
applications) and the  over-the-counter  market. The  over-the-counter  approval
process may include  additional  requirements  relating to self-testing with the
rapid test. We currently expect to develop an OTC HIV diagnostic  product at our
Rockville,  MD  facility  based on the license  and  technology  acquired in the
License Agreement.  We expect to begin the development  process for this product
no later than the first half of 2005 and  commence  the  regulatory  process for
professional  and OTC market  approval  with the US FDA in late 2005. We plan to
subsequently  develop  diagnostic  tests  for  other  STDs.  Failure  to  obtain
necessary regulatory approvals for our rapid tests would have a material adverse
effect on our business, financial condition and results of operations.

COMPETITION

Competition  in the  market  for HIV  testing  is  intense  and is  expected  to
increase.  We believe that the  principal  competition  will come from  existing
laboratory-based blood tests,  point-of-care rapid blood tests, oral fluid-based
tests,  or  other  laboratory-based  urine  assays  that may be  developed.  Our
competitors  include  specialized  biotechnology firms as well as pharmaceutical
companies with biotechnology divisions and medical diagnostic companies, many of
which  are   substantially   larger  and  have  greater   financial,   research,
manufacturing, and marketing resources.

Important  competitive factors for our products include product quality,  price,
ease of use, customer service, and reputation.  Industry competition is based on
the following:

     o     Scientific and technological capability;

     o     Proprietary know-how;

     o     The ability to develop and market products and processes;






We have  previously  indicated that our primary focus for 2004 is completing the
development and  commercialization  of certain rapid HIV tests. We have recently
completed  the second  phase of our initial  international  field  trials of our
developmental stage urine, blood and oral fluid rapid HIV tests in Thailand.  We
believe that the studies  validated the  technology  for all of our rapid tests.
All  three  assays  will  be  moved  into  manufacturing  sequentially.  We have
commenced  the  technology  transfer  of the blood  rapid  test to our  Thailand
manufacturer with the objective of completing our first pilot production lots by
year-end  2004.  We plan to  initiate  manufacturing  of the oral  fluid test in
Thailand shortly following the start-up of blood test  manufacturing.  The urine
test is expected to follow.  While we believe that the results of the urine test
to date are acceptable, scale-up is more difficult. Further, we believe that the
urine test used in the initial  trials can be improved  with respect to accuracy
as well as stability and reproducibility as we scale it up. We are investigating
what  improvements  are  necessary  prior to  initial  commercialization.  Urine
contains a lesser amount of antibody than either blood or oral fluid, making the
the   identification  of  those  individuals  with  low  levels  of  antibodies,
especially those who are receiving anti-retroviral therapy, even more difficult.
There can,  however,  be no assurance that we will complete the  development and
testing  process  of an  improved  urine  product  or that we will  successfully
manufacture and commercialize a urine rapid test, or our other rapid tests.





Gruß

C.O

 

 

Page 42

We are designing our rapid tests to comply with the rapid testing protocol
promulgated by WHO. Under that protocol, if a sample is non-reactive on the
basis of a single rapid test, testing is complete and the diagnosis is
considered negative for HIV infection. If the sample is reactive using the first
rapid test, it is tested with a second, different rapid test. A reactive sample
using the second test, having already been indicated as a presumptive positive
by the first test, is considered to be a positive diagnosis for HIV. A sample
that is non-reactive to the second test, after having been reactive to the first
test, is re-tested using a third, different rapid test. A reactive sample on the
third test is considered a positive diagnosis for HIV; a non-reactive sample is
considered a negative diagnosis.


xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx­x



Our research and development efforts are currently directed toward the
development of select high-priority new diagnostic tests, primarily for the
detection of HIV-1 and HIV-2. Priority is determined on the basis of
feasibility, probable cost to develop, ability to acquire necessary intellectual
property rights, regulatory complexity, market size and competition. Our product
development strategy includes both internal product development and partnering
with other companies to optimize existing tests and test formats and to obtain
freedom to operate in conformity with other companies' intellectual property
rights.

Page 42



xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx­xx



Page 43

Our urine test development efforts have identified certain unique product
properties and processes that we plan to protect. We believe that this
intellectual property is significant as it may result in a blocking patent to
those who may consider urine testing by protecting a key step necessary in
achieving the highest levels of specificity.

Incidence Tests. On April 14, 2004, we announced that we had executed a CRADA -
a Cooperative Research and Development Agreement - with the CDC for the
development of a new HIV rapid blood assay. Like current rapid test assays, the
proposed device will be for diagnostic use to detect HIV antibodies, but it will
also be used to determine the proportion of HIV-1 infections that have occurred
in the last six months. The purpose of the test is to provide a simplified and
rapid format that can be performed in resource poor settings and remote outreach
locations for diagnostic and surveillance purposes.

Over-the-Counter. There are currently no FDA approved over-the-counter ("OTC")
HIV test products providing an immediate diagnosis.


Nonethless, we believe there
may be interest in an over-the-counter in-home rapid test in a number of
countries worldwide. We currently expect to develop an OTC HIV diagnostic
product at our Rockville, MD facility based on the license and technology
acquired in the License Agreement. We expect to begin the development process
for this product no later than the first half of 2005 and commence the
regulatory process for professional and OTC market approval with the US FDA in
late 2005.




xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx­x






Page 44

We intend to develop and/or market additional or improved
tests, focusing on urine and oral fluid, for other infectious and viral
diseases, including other sexually transmitted diseases ("STDs"). We intend to
focus on developing and marketing products that are complementary to our
existing product lines, technical expertise and market opportunities.




Gruß

C.O
 

http://apha.confex.com/apha/132am/techprogram/exhibitor_407.htm
 

klar gibt es bald verkäufe, weitere aktienverkäufe...

ich bleibe dabei: augrid ist der bessere pick. eine frage der zeit, bis augrid caly von kurs her überholt hat und auch von den umsätzen im freien markt...  

dachte du bist normal, aber was du heute wieder hier von dir gibst ist nur noch lächerlich!
Noch nicht genug auf die Schnauze gefallen mit Augrid? nein? doch?
Am 08.10 in WO inn Ariva in jeden Thread Betrug S_EC Bestrafung und jetzt wieder diese Kommentare einfach läcerlich du bist ja wie das Fähnlein im Wind oder noch besser aus dem 30.Jährigen Krieg bei den Söldner" Wesen Brot ich ess dessen Lied ich sing".
Joelu du bist absolut unverbesserlich und in meinen Augen unseriös mit deinen Aussagen.

Position- Long; ST Rating- Strong Buy; LT Rating- Strong Buy

 

problem du hast lucky. das eine schliesst das andere überhaupt nicht aus. wenn gonzales uns bescheißt, schicke ich seine aussagen an die SEC. ganz einfach  

dann hast du bald eine kursexplosion. lt. einer schriftlichen aussage von ihm, ist augrid mit all seinen patenten und projekten das 30-fache von dem wert, wie sie momentan bewertet sind. laß ihn übertreiben und laß es nur das 10-fache sein, dann bist du bei einem kurs von mind. 0,65  

zu Augrid:

vielleicht solltest Du wissen, dass eine Bekanntgabe von Verträgen, Einnahmen, Geschäftszahlen... vor Veröffentlichung durch eine offizielle Pressemeldung weder legal noch zu dulden ist (in den USA wie auch bei uns).
Schon mal was von Insidertrading usw. gehört ?

Wie auch immer ist es also sehr unserioes und irgenwas faul...

Was sagst Du dazu ?
 

melde mich einfach bei der SEC...ich weiß nichts definitives über aufträge, aber was großes soll in der mache sein. wie groß, weiß ich nicht. aufgrund diverser aussagen/mails von gonzales ist das zumindestens fundierter als das übliche gepushe der leute, die nur über gerüchte sprechen. das es u.u. jenachdem, wie es formiliert ist ein schmaler grad ist, ist klar. ist mir aber auch egal. wichtig ist, dass es eingehalten wird.

und lucky, zu #2333: du hast sicherlich recht mit deiner kritik. also: werde mich bessern. werde dann wieder lauter werden, was augrid anbelangt, wenn sie wirklich mal über 0,20$ stehen. dann können sich unbeteiligte auch eher vorstellen, dass sich was tut. okay?  

http://www.calypte.com/PRODUCTS/INSERTS/...EIA%20Package%20Insert.pdf
 

 

Du meinst auf der ersten Seite links unten-  das scheint irgendeine Patent- oder Registrierungsnr. zu sein. Rechts unten ist das Copyright von Calypte von 2004.

Ist definitiv der neue Incidence Test von 2004.  

 

 

 

Position- Long; ST Rating- Strong Buy; LT Rating- Strong Buy

 

 

 

Position- Long; ST Rating- Strong Buy; LT Rating- Strong Buy

 

ansehen ;-)  

nächsten Montag eine PR zu den Incidence Tests & Sales veröffentlicht wird  

10/08/04 0.380 0.390 0.370 0.370 412,200 –  –  
10/07/04 0.380 0.390 0.370 0.370 373,900 –  –  
10/06/04 0.390 0.398 0.370 0.370 614,900    0.010  -2.632%  
10/05/04 0.400 0.440 0.380 0.380 2,274,100    0.010  -2.564%  
10/04/04 0.380 0.400 0.380 0.390 418,700    0.010   2.632%  
10/01/04 0.390 0.390 0.380 0.380 335,200    0.010  -2.564%  
09/30/04 0.380 0.390 0.370 0.390 307,600    0.010   2.632%  
09/29/04 0.380 0.390 0.370 0.380 336,300 –  –  
09/28/04 0.410 0.410 0.380 0.380 548,900    0.010  -2.564%  
09/27/04 0.430 0.430 0.390 0.390 215,800    0.030  -7.143%  
09/24/04 0.390 0.440 0.380 0.420 930,500    0.030   7.692%  
09/23/04 0.390 0.400 0.380 0.390 357,300    0.010   2.632%  
09/22/04 0.390 0.400 0.380 0.380 78,800    0.010  -2.564%  
09/20/04 0.390 0.430 0.380 0.390 717,200    0.020  -4.878%  
09/17/04 0.410 0.410 0.380 0.410 290,700 –  –  
09/16/04 0.420 0.420 0.390 0.410 156,100    0.010  -2.381%  
09/15/04 0.390 0.420 0.380 0.420 548,300    0.040   10.526%  
09/14/04 0.380 0.400 0.370 0.380 142,300 –  –  
09/13/04 0.380 0.390 0.370 0.380 361,600    0.010   2.703%  
09/10/04 0.400 0.400 0.360 0.370 1,901,300    0.030  -7.500%  
09/09/04 0.400 0.419 0.390 0.400 167,700    0.020  -4.762%  
09/08/04 0.410 0.420 0.390 0.420 209,000    0.010   2.439%  
09/07/04 0.410 0.440 0.410 0.410 129,100 –  –  
09/03/04 0.390 0.430 0.390 0.410 478,700    0.020   5.128%  
09/02/04 0.410 0.420 0.370 0.390 910,700    0.020  -4.878%  
09/01/04 0.410 0.410 0.400 0.410 555,500    0.010   2.500%  
08/31/04 0.420 0.420 0.400 0.400 337,600    0.010  -2.439%  
08/30/04 0.430 0.440 0.410 0.410 356,400    0.010  -2.381%  
08/27/04 0.420 0.430 0.400 0.420 470,700 –  –  
08/26/04 0.430 0.430 0.400 0.420 332,800    0.010   2.439%  
08/25/04 0.430 0.430 0.400 0.410 450,600    0.020  -4.651%  
08/24/04 0.450 0.450 0.410 0.430 392,000    0.020  -4.444%  
08/23/04 0.430 0.470 0.430 0.450 503,400    0.010  -2.174%  
08/20/04 0.470 0.490 0.450 0.460 140,300    0.010  -2.128%  
08/19/04 0.490 0.490 0.450 0.470 480,400    0.010  -2.083%  
08/18/04 0.510 0.530 0.460 0.480 413,700    0.480   %  

Der Kurs wird abgeriegelt nach oben, oder sehe ich das falsch?

Genau so werden wir heute wiederrum nicht im plus schließen, weil der Kurs bei 0,37 oder bei 0,36 eingefroren ist

Position- Long; ST Rating- Strong Buy; LT Rating- Strong Buy